REPORTS

Let’s Pullulate and Expand Your Business

Neuroprotective Drugs Market - Global Professional Analysis and Forecast to 2026

Jan 26, 2020  |  224 PAGES  |  REPORT CODE: CMM263538
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Neuroprotective Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.3% during the forecast period.

This report presents the market size and development trends by detailing the Neuroprotective Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Neuroprotective Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Neuroprotective Drugs industry and will help you to build a panoramic view of the industrial development.

Neuroprotective Drugs Market, By Type:

  • Cholinesterase inhibitors

  • Anti-inflammatory

  • Others

Neuroprotective Drugs Market, By Application:

  • Alzheimer's disease

  • Parkinson's disease

  • Others

Some of the leading players are as follows:

  • Neuren Pharmaceuticals (Australia)

  • Ceregene (USA)

  • Bionure Inc. (USA)

  • Allon therapeutics (Canada)

  • BHRPharma (Thailand)

  • NeuroVive Pharmaceutical (Sweden)

  • Genervon Biopharmaceuticals (Canada)

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Neuroprotective Drugs Market: Technology Type Analysis

  • 4.1 Neuroprotective Drugs Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Neuroprotective Drugs Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Cholinesterase inhibitors

    • 4.3.2 Anti-inflammatory

    • 4.3.3 Others

5 Neuroprotective Drugs Market: Product Analysis

  • 5.1 Neuroprotective Drugs Product Market Share Analysis, 2018 & 2026

  • 5.2 Neuroprotective Drugs Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Neuroprotective Drugs Market: Application Analysis

  • 6.1 Neuroprotective Drugs Application Market Share Analysis, 2018 & 2026

  • 6.2 Neuroprotective Drugs Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Alzheimer's disease

    • 6.3.2 Parkinson's disease

    • 6.3.3 Others

7 Neuroprotective Drugs Market: Regional Analysis

  • 7.1 Neuroprotective Drugs Regional Market Share Analysis, 2018 & 2026

  • 7.2 Neuroprotective Drugs Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Neuren Pharmaceuticals (Australia)

    • 9.1.1 Neuren Pharmaceuticals (Australia) Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Ceregene (USA)

    • 9.2.1 Ceregene (USA) Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Bionure Inc. (USA)

    • 9.3.1 Bionure Inc. (USA) Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Allon therapeutics (Canada)

    • 9.4.1 Allon therapeutics (Canada) Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 BHRPharma (Thailand)

    • 9.5.1 BHRPharma (Thailand) Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 NeuroVive Pharmaceutical (Sweden)

    • 9.6.1 NeuroVive Pharmaceutical (Sweden) Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Genervon Biopharmaceuticals (Canada)

    • 9.7.1 Genervon Biopharmaceuticals (Canada) Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

 

The List of Tables and Figures (Totals 105 Figures and 136 Tables)

  • Figure Cholinesterase inhibitors Neuroprotective Drugs market, 2015 - 2026 (USD Million)

  • Figure Anti-inflammatory Neuroprotective Drugs market, 2015 - 2026 (USD Million)

  • Figure Others Neuroprotective Drugs market, 2015 - 2026 (USD Million)

  • Figure Alzheimer's disease market, 2015 - 2026 (USD Million)

  • Figure Parkinson's disease market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Neuroprotective Drugs market, by country, 2015 - 2026 (USD Million)

  • Table North America Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table North America Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table North America Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Canada Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Canada Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Europe Neuroprotective Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Europe Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Europe Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Europe Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Germany Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Germany Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table France Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table France Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Italy Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Italy Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Spain Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Spain Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neuroprotective Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table China Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table China Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Japan Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Japan Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table India Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table India Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Neuroprotective Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table MEA Neuroprotective Drugs market, by country, 2015 - 2026 (USD Million)

  • Table MEA Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table MEA Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table MEA Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Neuroprotective Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Neuroprotective Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Neuroprotective Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Neuren Pharmaceuticals (Australia) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Ceregene (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bionure Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allon therapeutics (Canada) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BHRPharma (Thailand) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table NeuroVive Pharmaceutical (Sweden) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Genervon Biopharmaceuticals (Canada) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top